Hormone therapy brands, and the three claims that draw the closest reading

Hormone therapy is one of the fastest-growing direct-to-consumer telehealth categories and one of the least uniform. A single brand may sell an approved product prescribed generically, a compounded preparation, a supplement and a laboratory panel, and the rules for each are different.

Certification in this category is ordinary. What is not ordinary is how many distinct compliance questions one catalogue can contain.

Three overlapping problems in one brand

A compounded preparation problem. Creams, troches, pellets and combination formulations are compounded, they are not approved products, and they may not be described as though they were. Everything in the compounded marketing rules applies here unchanged, because the underlying issue is identical.

A controlled substance problem. Some formulations in this category are controlled, which pulls the whole application into a more documented review. That is not a reason to avoid the category, and it is a reason to have the framework written down before filing, as controlled substances and telehealth certification sets out.

A claims problem specific to ageing. This is the one the category owns, and it is where most of the attention lands.

The optimisation vocabulary

Hormone brands market against a feeling rather than a diagnosis: tired, heavier, foggier, older. The language that converts is the language of restoration and optimisation, and it makes claims in three ways at once.

It promises outcomes. Energy, body composition, libido, mood, sleep, performance. Presented as expected results, these are effectiveness claims about preparations that have not been reviewed for effectiveness.

It medicalises a normal state. Copy implying that ageing is a deficiency requiring treatment describes a model where almost everybody qualifies, which is precisely the pattern that makes a reviewer ask whether the prescribing decision is real.

It borrows authority. Trial results from an approved product, presented for a compounded one. Clinical-sounding thresholds presented as universally accepted. A named protocol described as though it were a standard.

The rewrite is the same one as everywhere else: describe the service honestly, name the preparation for what it is, and let the clinical process do the reassuring.

Testing, and what it implies

Most brands in this category sell or arrange laboratory testing, which raises its own questions.

Who orders the test, and are they licensed where the patient is? Who interprets it, and is that a clinician or an algorithm? Are the reference ranges the lab's or the brand's, and if they are the brand's, on what basis? Does a result that falls outside your treatment criteria actually produce a decline, and can you show that it does?

A brand whose testing exists to qualify patients rather than to assess them has built the clinical equivalent of a quiz that always says yes, and it is visible in the same way.

Supplements sold beside prescriptions

Nearly universal in this category and rarely handled well. A supplement sold in the same cart, in the same bundle, under the same brand, with structure and function language beside a prescription product tends to read as a disease claim by association.

Separate them visually, commercially and in the copy. Different pages, different carts where practical, and no bundle whose description makes a claim the supplement half cannot support.

What a reviewer will want established

• Which products are approved, which are compounded, and which are supplements, stated by you rather than inferred.
• Who compounds, under what registration, and whether your preparations sit inside its permitted scope.
• Which formulations are controlled, in which jurisdictions, and what framework governs prescribing them.
• What the intake screens for, and what produces a decline.
• Who orders and interprets testing, and under what licensure.
• What the marketing promises, read against all of the above.

The pellet and the compounded cream problem

Two formats deserve naming because they generate more questions than the rest of the category combined.

Pellets are inserted rather than dispensed, which means a procedure, a person performing it and a location. That is a different clinical model from posting a vial, and it needs describing as one: who performs the insertion, under what licensure, where, and what happens if there is a complication. Brands that present a procedure as a subscription have described something the site cannot support.

Compounded creams and troches invite dosing claims because the strength is chosen. Where the individualisation is a prescriber selecting among a handful of standard strengths, describing it as a bespoke formulation makes a claim about the product rather than about the service, which is the same distinction the personalisation language runs into everywhere else in compounding.

Where brands in this category usually stand

Better than they fear clinically and worse than they think on the website. The prescribers are real, the labs are real, the pharmacy relationship is documented, and the landing page was written to a conversion brief by somebody who had never been told that a promise about energy levels is a claim about a drug.

That position is fixable before submission and expensive to fix during a review, which is the difference between a short review and a rework loop.

An audit specific to this category

Six checks, on your own funnel, before anybody else runs them.

• Read every outcome word on the site and ask which product it attaches to and what evidence exists for that product.
• Find every place a compounded preparation is described without the word compounded.
• Check whether your intake can produce a decline, and how often it does.
• Read the testing pages for who orders, who interprets, and against whose reference ranges.
• Look at the shop for supplements and prescriptions sharing a bundle or a claim.
• List which formulations are controlled and confirm the framework for them exists as a document rather than as a practice.

Most brands find three or four things. All of them are cheaper this week than they will be in the second round of correspondence.